Is Teract (EPA:TRACT) Using Debt In A Risky Way?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' So it seems the smart money knows that debt - which is usually involved in bankruptcies - is a very important factor, when you assess how risky a company is. We note that Teract S.A. (EPA:TRACT) does have debt on its balance sheet. But the more important question is: how much risk is that debt creating?

Advertisement

When Is Debt Dangerous?

Debt and other liabilities become risky for a business when it cannot easily fulfill those obligations, either with free cash flow or by raising capital at an attractive price. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. While that is not too common, we often do see indebted companies permanently diluting shareholders because lenders force them to raise capital at a distressed price. Of course, the upside of debt is that it often represents cheap capital, especially when it replaces dilution in a company with the ability to reinvest at high rates of return. The first step when considering a company's debt levels is to consider its cash and debt together.

What Is Teract's Debt?

As you can see below, Teract had €337.0m of debt, at December 2024, which is about the same as the year before. You can click the chart for greater detail. However, it does have €11.6m in cash offsetting this, leading to net debt of about €325.4m.

debt-equity-history-analysis
ENXTPA:TRACT Debt to Equity History June 19th 2025

How Healthy Is Teract's Balance Sheet?

According to the last reported balance sheet, Teract had liabilities of €450.7m due within 12 months, and liabilities of €418.6m due beyond 12 months. Offsetting this, it had €11.6m in cash and €120.5m in receivables that were due within 12 months. So its liabilities outweigh the sum of its cash and (near-term) receivables by €737.2m.

The deficiency here weighs heavily on the €67.8m company itself, as if a child were struggling under the weight of an enormous back-pack full of books, his sports gear, and a trumpet. So we'd watch its balance sheet closely, without a doubt. At the end of the day, Teract would probably need a major re-capitalization if its creditors were to demand repayment. When analysing debt levels, the balance sheet is the obvious place to start. But it is Teract's earnings that will influence how the balance sheet holds up in the future. So when considering debt, it's definitely worth looking at the earnings trend. Click here for an interactive snapshot.

View our latest analysis for Teract

In the last year Teract had a loss before interest and tax, and actually shrunk its revenue by 3.4%, to €910m. We would much prefer see growth.

Caveat Emptor

Over the last twelve months Teract produced an earnings before interest and tax (EBIT) loss. Its EBIT loss was a whopping €27m. When you combine this with the very significant balance sheet liabilities mentioned above, we are so wary of it that we are basically at a loss for the right words. Sure, the company might have a nice story about how they are going on to a brighter future. But the reality is that it is low on liquid assets relative to liabilities, and it lost €66m in the last year. So we think buying this stock is risky. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. These risks can be hard to spot. Every company has them, and we've spotted 2 warning signs for Teract (of which 1 shouldn't be ignored!) you should know about.

If, after all that, you're more interested in a fast growing company with a rock-solid balance sheet, then check out our list of net cash growth stocks without delay.

Valuation is complex, but we're here to simplify it.

Discover if Teract might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About ENXTPA:TRACT

Teract

Engages in the retail business in France and rest of Europe.

Slightly overvalued with imperfect balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
CUE logo
Lou_Basenese on Cue Biopharma ·

Cue Biopharma (NASDAQ: CUE): The Scientist Behind Xolair Just Gave Cue a Next-Generation Shot at the Same Multi-Billion-Dollar Market

Fair Value:US$7060.2% undervalued
25 users have followed this narrative
0 users have commented on this narrative
5 users have liked this narrative
HA
HarishPK
ADBE logo
HarishPK on Adobe ·

Adobe: A Probabilistic Case for Undervaluation

Fair Value:US$317.226.4% undervalued
32 users have followed this narrative
7 users have commented on this narrative
10 users have liked this narrative
NI
niteco
AVGO logo
niteco on Broadcom ·

A Capital Allocation Favorite with Structural Importance

Fair Value:US$651.0542.8% undervalued
33 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
TO
Tokyo
OKTA logo
Tokyo on Okta ·

Good foundation, but now it's all about the next steps

Fair Value:US$15123.9% undervalued
85 users have followed this narrative
7 users have commented on this narrative
11 users have liked this narrative

Updated Narratives

AN
AntonioS
CSL logo
AntonioS on CSL ·

CSL Investment Thesis

Fair Value:AU$14026.5% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7448.9% undervalued
58 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
VA
Valtersa
4002 logo
Valtersa on Mouwasat Medical Services ·

Mouwasat Medical Services Will Achieve a 25% Profit Margin in Just 3 Years

Fair Value:ر.س98.634.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

MA
martinarauz
NU logo
martinarauz on Nu Holdings ·

Investment Analysis (May 2026)

Fair Value:US$22.7448.9% undervalued
58 users have followed this narrative
0 users have commented on this narrative
15 users have liked this narrative
CL
Clive_Thompson
TTWO logo
Clive_Thompson on Take-Two Interactive Software ·

Take-Two Interactive: The Calm Before the Storm NASDAQ: TTWO Last Price: $242.41 Date: May 15, 2026

Fair Value:US$276.9724.0% undervalued
58 users have followed this narrative
0 users have commented on this narrative
14 users have liked this narrative
NI
niteco
HON logo
niteco on Honeywell International ·

Honeywell - The Demand-Side of the AI Infrastructure

Fair Value:US$320.1935.7% undervalued
48 users have followed this narrative
0 users have commented on this narrative
19 users have liked this narrative